



# LUND UNIVERSITY

## Tuberculosis along the continuum of HIV care in a cohort of adolescents living with HIV in Ethiopia

Jerene, Degu; Abebe, W.; Taye, K.; Suarez, P. G.; Feleke, Y.; Hallström, I.; Ruff, A. J.

*Published in:*  
International Journal of Tuberculosis and Lung Disease

*DOI:*  
[10.5588/ijtld.16.0105](https://doi.org/10.5588/ijtld.16.0105)

2017

*Document Version:*  
Peer reviewed version (aka post-print)

[Link to publication](#)

*Citation for published version (APA):*  
Jerene, D., Abebe, W., Taye, K., Suarez, P. G., Feleke, Y., Hallström, I., & Ruff, A. J. (2017). Tuberculosis along the continuum of HIV care in a cohort of adolescents living with HIV in Ethiopia. *International Journal of Tuberculosis and Lung Disease*, 21(1), 32-37. <https://doi.org/10.5588/ijtld.16.0105>

*Total number of authors:*  
7

### General rights

Unless other specific re-use rights are stated the following general rights apply:  
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

1 **Tuberculosis along the continuum of HIV care in a cohort of adolescents**  
2 **living with HIV in Ethiopia**

3

4 *Degu Jerene*\*<sup>1</sup>, *Workeabeba Abebe*<sup>2</sup>, *Kefyalew Taye*<sup>3</sup>, *Pedro G. Suarez*<sup>4</sup> *Inger Hallström*<sup>5</sup>,  
5 *Andrea J. Ruff*<sup>6</sup>

6

7

8 <sup>1</sup> Management Sciences for Health, Addis Ababa, Ethiopia

9 <sup>2</sup> Addis Ababa University, Department of Pediatrics and Child Health, Addis Ababa, Ethiopia

10 <sup>3</sup> Hawassa University, Department of Pediatrics and Child Health, Hawassa, Ethiopia

11 <sup>4</sup> Management Sciences for Health, Center for Health Services, Arlington, Virginia, USA

12 <sup>5</sup> Lund University, Faculty of Medicine, Department of Health Sciences, Sweden

13 <sup>6</sup> Johns Hopkins University, Bloomberg School of Public Health, Department of International  
14 Health, Baltimore, USA

15

16 **Running head:** TB in adolescents living with HIV

17

18 **Word Count (Summary): 200**

19 **Words: 2500** (excluding summary, tables and references)

20 **Number of tables:** 3

21 **Number of figures:** 0

22 **Number of references:** 28

23 **Key words:** TB incidence, INH preventive therapy, pre-ART

24

25 **\*Corresponding author:**

26 Degu Jerene MD, PhD

27 P.O.Box 1157, Code 1250

28 Addis Ababa, Ethiopia

29 Phone: +251-116-620-781

30 Fax: +251-116-616-825

31 Email: [degujerene@gmail.com](mailto:degujerene@gmail.com)

32

33 **Summary**

34 **Setting:** Eight health facilities in two regions of Ethiopia

35 **Objective:** To determine TB incidence rates and associated factors among adolescents  
36 living with HIV in Ethiopia.

37 **Design:** This was a retrospective cohort study. Adolescents enrolled in HIV care between  
38 January 2005-December 31 2013 constituted the study population. The main outcome variable  
39 was diagnosis of TB during follow up. Baseline WHO clinical stage, CD4 count, previous  
40 history of TB and the use of isoniazid preventive therapy (IPT) were main independent variables.  
41 We estimated TB incidence rates as incident cases per 100 person-years of observation (PYO).  
42 The Cox regression analysis was used to control for confounders.

43 **Results:** Of 1072 adolescents studied, 60.1% were girls. TB incidence rate was 16.32 per  
44 100 PYO during pre-antiretroviral therapy (pre-ART) follow up but declined to 2.25 per 100 PY  
45 after initiation of ART. Advanced WHO clinical stage (adjusted Hazard Ratio, aHR=2.71; 95%  
46 CI=1.69, 4.33) and CD4 count <350 cells/ml [(aHR=2.28 (1.10, 4.81)] predicted TB incidence in  
47 the pre-ART cohort. IPT use was associated with significant reduction in TB incidence in the  
48 ART cohort.

49 **Conclusion:** TB was a significant problem in adolescents living with HIV but it can be  
50 reduced significantly if ART and IPT are administered adequately.

51

## 52 INTRODUCTION

53 Tuberculosis (TB) is a global public health problem, with about 9 million new infections  
54 and 1.5 deaths occurring in a year.<sup>1</sup> People living with HIV (PLHIV) comprised 13% of all TB  
55 deaths. However, there is limited data on the contribution of TB in adolescents to the global TB  
56 burden. In fact, lack of adolescent-specific health data is a global challenge.<sup>2</sup> Older  
57 epidemiologic data suggest increased incidence of TB during adolescence<sup>3,4</sup>, and the risk of TB  
58 infection is highest during infancy and adolescence.<sup>5-7</sup> More recent data suggested high  
59 prevalence of TB among adolescents aged 12-18 years.<sup>8</sup>

60 Since adolescents are socially active, their potential to transmit to their peers is high and  
61 risk factors such as smoking, substance use, and stress are more common among adolescents  
62 increasing their likelihood of developing TB and eventually transmitting to their peers.<sup>9-11</sup> Also,  
63 with more and more perinatally HIV infected children growing to adolescence, it is important to  
64 have clearer understanding of both the magnitude and factors contributing to TB incidence in this  
65 age group in order to plan for appropriate preventive measures.<sup>10,11</sup>

66 Data on the magnitude and determinants of TB among adolescents are scarce and when  
67 reported, they are not generally focused on HIV infected adolescents or separately report on the  
68 age group 10-19 years of age.<sup>8, 12-14</sup> Our objective was to determine the magnitude of TB among  
69 adolescents at each phase of HIV care cascade in a cohort of ALHIV treated and followed at  
70 selected public health facilities in Ethiopia.<sup>15</sup>

71

## 72           **METHODS**

### 73           **Study setting**

74           This study was conducted in eight health facilities in Addis Ababa and Southern  
75 Nations', Nationalities' and Peoples' Regional State (SNNPR) regions of Ethiopia. Addis Ababa  
76 is the capital city of Ethiopia whereas SNNPR is a predominantly rural region, although most of  
77 HIV patients are concentrated in urban areas even in SNNPR. The eight health facilities were  
78 selected based on the high load of ALHIV, according to the investigators' prior knowledge about  
79 the sites. Despite the good progress made in preventing and controlling HIV and TB, Ethiopia  
80 belongs to high HIV and TB burden countries.<sup>16, 1</sup>

### 81           **Study design**

82           We used a retrospective cohort study design. The study population constituted  
83 adolescents (age 10-19 years inclusive) enrolled in chronic HIV care between January 2005-  
84 December 31 2013. Participants had to have at least one documented clinic visit and be ART-  
85 naïve at the time of enrolment in chronic HIV care in the study clinic.

86           Per the national guidelines, all PLHIV were screened for symptoms of TB at baseline and  
87 then at each clinic visit. Symptomatic patients received further clinical evaluation and diagnostic  
88 tests. The first line diagnostic test during the cohort period was conventional sputum microscopy.  
89 Chest radiography was done on selected cases upon physicians' recommendation. Rapid TB  
90 diagnostic tests were not part of the national guidelines at the time this cohort was enrolled.<sup>17</sup>

91           To calculate the sample size, we used the baseline WHO clinical stage as main predictor  
92 of TB and those in stage III-IV were considered "exposed" groups. Assuming a two-sided alpha  
93 of 0.05, power of 0.8, TB in the exposed group as 10%, and TB in the unexposed group as 5%,  
94 we calculated minimum sample size of 948. The assumptions were based on preliminary  
95 analyses of data from ongoing larger cohort study in the study site. Using an electronic access  
96 database maintained at each ART clinic, we generated age-stratified list of patients as a sampling  
97 frame. Since the number of eligible adolescents was close to the estimated sample size, we  
98 included all eligible adolescents in the study.

### 99           **Data collection and management**

100           We used patient charts and registers as data sources. At each site, two study nurses  
101 assisted by data clerks retrieved information using a data abstraction form. At the end of each  
102 work week, the site study nurses submitted all completed data abstraction forms to the co-

103 investigator in the respective region. The co-investigator, who is a pediatrician with specialist  
104 level training in HIV, checked for errors and omissions and forwarded the paper data forms to  
105 the centrally based research assistant for further quality check and for secure storage. A centrally  
106 based data clerk entered data from checked and approved data abstraction forms into SPSS  
107 version 22.0. Electronic data were stored in a password protected data storage device and the  
108 paper data forms were kept in a lockable shelf. No patient identifiers were included in the  
109 electronic data.

110 The data abstraction tool was piloted in a few sites before starting actual data abstraction.  
111 All staff involved in data management were trained on the standard operating procedures of the  
112 study protocol. The principal author did random checks of the completed data abstraction forms  
113 at regular intervals.

#### 114 **Definitions**

115 The main outcome variable was diagnosis of TB during follow up as confirmed and  
116 recorded in patient registers according to the national guidelines by the treating clinician.<sup>24</sup>  
117 Patients in whom TB diagnosis was confirmed at least four weeks after the patient was in pre-  
118 ART care but before the ART start date were defined to have **pre-ART TB**. Patients who  
119 developed TB after four weeks of ART initiation were considered to have **TB during ART**.

120 We determined **IPT completion rates** from patient registers. Those who completed a 6-  
121 month course of IPT and labelled by the clinicians as such were considered “completed”; those  
122 who received for less than 6 months were categorized as “did not complete”; and those with  
123 missing information were categorized as “no information”.

124 Information on **adherence to co-trimoxazole therapy (CPT)** was also retrieved from  
125 patient registers. Clinicians recorded either “good” or “poor” based on patients’ self-report. We  
126 determined the adherence status as per the clinician’s record during the patients’ last visit.

#### 127 **Data analysis**

128 We used SPSS version 22 for data analysis. We calculated TB incidence rate as number  
129 of new episodes of TB per 100-person years of observation. We checked for patterns of missing  
130 data and used list-wise deletion method for missing variables. A cox regression survival analysis  
131 was used to control for potential confounders. TB diagnosis (as defined above) was the main  
132 outcome variable. We included baseline WHO clinical stage, CD4 count (categorized as <350  
133 versus ≥350 cells/ml for the pre-ART cohort and <200 versus ≥200 cells/ml for the ART

134 cohort), history of cough of more than 2 weeks, and IPT (ever used or not). Co-variables included  
135 sex and address (as urban or rural) in the Cox model. Co-variables which had a p-value of <0.25  
136 in the univariate model were included in to the multivariate model. Two-sided  $p < 0.05$  was  
137 considered statistically significant.

### 138 **Ethics**

139 National, Regional and Institutional Review committees approved the protocol. All  
140 research staff were trained on the ethical conduct of Human Subjects Research. Measures to  
141 protect data security and confidentiality are described above.

142

143

## 144 **RESULTS**

### 145 **Baseline characteristics**

146 Of 1,221 adolescents screened, 1,072 fulfilled the eligibility criteria and were included in  
147 the analysis; 60.1% were girls and 87% came from urban areas. Half (50.7%) presented at an  
148 advanced WHO stage. Baseline CD4 values were available for 95.3% of patients and their  
149 median CD4 count per ml was 228. Table 1 describes baseline characteristics of the participants.  
150 Only 142 (13.2%) of the patients received IPT during the entire follow up (57 during pre-ART  
151 follow up and 85 at, or after ART initiation). Of these, 103 (72.5 %) completed full course of  
152 IPT, 22 (15.5%) did not complete, and information was missing in 17 (12%). On the other hand,  
153 84.5% of adolescents received CPT with 68.9% of them reported to have good CPT adherence  
154 rate at last visit.

### 155 **TB during pre-ART follow up**

156 Previous history of TB was present in 171 (16%) of the participants. A further 149  
157 (13.9%) had history of TB at enrollment of which 50.3% had smear positive pulmonary TB,  
158 28.8% smear negative pulmonary TB, 14.1% extra-pulmonary TB, and type of TB was not  
159 recorded in 6.7%. The total pre-ART follow up period was 870.03 PYO during which 142  
160 adolescents were diagnosed with active TB. Of these, 46% had previous history of TB at  
161 baseline. The TB incidence density (95% Confidence Interval, CI) was 16.32 (13.75, 19.24) per  
162 100 PY.

163 Having advanced WHO clinical stage (aHR=5.68; 95% CI=3.72-8.68), CD4 count <350  
164 count per ml at baseline (aHR=1.85 95% CI=1.21, 2.84), previous history of TB (aHR=2.22;  
165 95% CI=1.51-3.26), and history of cough of > 2 weeks (aHR=4.25; 95%CI=2.81-6.44) predicted  
166 TB. IPT was associated with reduction in TB incidence rate but this was not statistically  
167 significant (aHR=0.55; 95% CI=0.16-1.91). See **Table 2**.

### 168 **TB after ART initiation**

169 Of 816 put on ART, 98 were on anti-TB treatment at ART initiation including 58 in  
170 intensive and 40 in continuation phases of treatment. Further, 64 patients developed TB during  
171 2843.53 PYO, yielding TB incidence rate of 2.25 (95% CI, 1.78-2.86) per 100 PYO after ART  
172 initiation. The incidence rate was highest during the first year of ART (16.7 per 100 PYO)  
173 compared with 2.3 and 1.6 per 100 PYO between 1-5 yr and more than 5 yr respectively. Being  
174 in advanced WHO clinical stage (aHR=1.23; 95% CI=0.63, 2.38); having CD4 count <200



175 cells/ml at baseline (aHR=1.92; 95% CI=1.07, 3.43); and being from SNNPR (aHR=2.69; 95%  
176 CI=1.52, 4.78) predicted higher TB rates. On the other hand, IPT use was associated with  
177 significantly lower TB incidence rate (aHR=0.06; 95%CI=0.01, 0.45). Table 3 summarizes  
178 results for the ART cohort.

179

## DISCUSSION

180  
181 This is the first report of ALHIV-specific TB data from Ethiopia and perhaps one of a  
182 few globally. We found a high TB incidence rate among ALHIV, especially during pre-ART and  
183 the first year of ART, and declined sharply after the first year of ART. Low baseline CD4 values,  
184 advanced clinical disease stage, previous history of TB, and presence of prolonged cough at  
185 baseline predicted occurrence of TB. IPT was associated with 94% reduction in TB incidence  
186 rate in the ART cohort. Our findings suggest the need to prioritize ALHIV for TB prevention and  
187 highlight the need to be watchful for specific risk factors during clinical care of adolescents.

188 Both the pre-ART and after ART TB rates in our cohort are at least ten times higher than  
189 those reported among non-HIV infected adolescents. In a rural Uganda, for example, the  
190 incidence of TB among adolescents aged 12-18 years was 0.235 per 100 PYO.<sup>13</sup> Among  
191 adolescents in a South African school, TB incidence rate was 0.45 per 100 PYO.<sup>18</sup>

192 The pre-ART TB incidence rate in our study is higher than what was reported in adult  
193 cohorts from similar settings. In two reports from southern Ethiopia, pre-ART TB incidence  
194 ranged from 9.9-11.1 per 100 PYO.<sup>19, 20</sup> However, the overall TB incidence rate of 2.25 per 100  
195 PYO in adolescents who received ART in our study is lower than a rate of 3.7 per 100 PYO in an  
196 adult cohort from southern Ethiopia.<sup>20</sup> In Addis Ababa, TB incidence rate was 3.1 per 100 PYO  
197 in adult cohort of patients on ART.<sup>21</sup> In a South African adult cohort, TB incidence rate declined  
198 from 3.5 per 100 PYO in the first year to 1.01 per 100 PYO in the fifth year.<sup>22</sup> The heightened  
199 risk of TB among adolescents in the current study despite improved TB prevention and control  
200 efforts in Ethiopia is a clear indication to prioritize ALHIV as key populations for TB  
201 prevention.<sup>1</sup>

202 The predictive value of CD4 count and WHO clinical stage are well documented in adult  
203 cohorts.<sup>23, 24</sup> We found similar results in the pre-ART cohort but we did not find significant  
204 association between TB incidence and WHO clinical stage after ART. This suggests that CD4  
205 count may be a more reliable predictor of TB incidence in the adolescent cohort compared with  
206 the WHO clinical stage.

207 Despite its proven effectiveness, IPT coverage was low in this age group. Our finding  
208 concurs with results from similar settings. This further confirms the need to strengthen IPT  
209 implementation.<sup>24</sup>

210 The higher TB incidence rate among ART patients from SNNPR was an unexpected  
211 finding. It could be a reflection of variations in disease burden or a result of differences in case  
212 finding efforts. Further analysis of epidemiologic data is needed to better explain the regional  
213 variations. .

214 Previous history of TB was associated with more than doubling in the risk of TB in this  
215 cohort. Earlier studies among adult cohorts reported conflicting results <sup>22</sup>, but a more recent study  
216 from Brazil reported doubling in the risk of TB in patients who had previous history of TB, and  
217 about 38% of the patients in that report had previous history of TB.<sup>26</sup> In our cohort, about 46% of  
218 patients who developed TB during pre-ART follow up had previous history of TB which could  
219 be due to the higher overall TB burden in Ethiopia.<sup>1</sup> Reinfection due to weakened immune status  
220 is the underlying reason for TB recurrence in PLHIV. <sup>27, 28</sup> Since our cohort includes patients  
221 from pre-ART era over a decade ago, they might have had TB and treatment for it long before  
222 starting ART. Our finding suggests the need for including previous history of TB as part of the  
223 routine screening checklists in high TB/HIV burden settings.

224 Our study has some limitations. TB diagnosis was made based on microscopy or  
225 radiography potentially leading to underestimation of incident TB cases because of the low  
226 sensitivity of the diagnostic method. Because of the retrospective data collection method, we  
227 were not able to determine the outcomes of treated TB cases and data were missing on some key  
228 potential predictors such as smoking. Nevertheless, to our knowledge these are the first  
229 adolescent-specific TB data among PLHIV in Ethiopia and likely will have broader implications  
230 with increasing numbers of HIV-infected adolescents globally.

231

232           **CONCLUSIONS**

233           We found a high rate of TB incidence among ALHIV in public health facilities in two  
234 regions of Ethiopia. IPT and ART had protective effect. However, the IPT coverage rate was  
235 unacceptably low in this age group. The first year of ART was the period with highest rates of  
236 incident TB cases followed by the pre-ART period. TB programs should prioritize ALHIV as  
237 priority target groups for TB prevention and control efforts, especially up to the first year after  
238 ART. Strengthening school TB programs, contact investigation among adolescents, early IPT  
239 and adequate IPT coverage should be considered urgent priorities. Prospective studies with more  
240 comprehensive variables will provide further insights about the high TB rate in this age group.

241           **ACKNOWLEDGEMENTS**

242           We thank site study coordinators and data clerks for their work. The study was funded by  
243 a CIPHER grant from the International AIDS Society, supported by ViiV Healthcare. The views  
244 expressed in this publication do not necessarily reflect the official policies of the International  
245 AIDS Society or ViiV Healthcare. This publication was made possible in part with help from the  
246 Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189),  
247 which is supported by the following NIH Co-Funding and Participating Institutes and Centers:  
248 NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. The  
249 content is solely the responsibility of the authors and does not necessarily represent the official  
250 views of the NIH.

251           **CONFLICT OF INTEREST**

252           None declared.

253

254 **References**

255

- 256 1. World Health Organization (2014). Global tuberculosis report. Geneva, Switzerland.
- 257 2. Patton GC, Coffey C, Cappa C, et al. Health of the world's adolescents: a synthesis of  
258 internationally comparable data. *Lancet*. 379(9826):1665-75.
- 259 3. Barry MA, Shirley L, Grady MT, et al. Tuberculosis infection in urban adolescents:  
260 results of a school-based testing program. *Am J Public Health*. 1990;80(4):439-41.
- 261 4. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-  
262 dependent risks of disease and the role of reinfection. *Epidemiol and Infect*.  
263 1997;119(2):183-201.
- 264 5. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood Pulmonary  
265 Tuberculosis. *Am J Respir Crit Care Med*. 2006;173(10):1078-90.
- 266 6. Marais BJ, Gie RP, Schaaf HS, et al. The clinical epidemiology of childhood pulmonary  
267 tuberculosis: a critical review of literature from the pre-chemotherapy era [State of the  
268 Art]. *Int J Tuberc Lung Dis*. 2004;8(3):278-85.
- 269 7. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic  
270 tuberculosis: a critical review of literature from the pre-chemotherapy era [State of the  
271 Art]. *Int J Tuberc Lung Dis* 2004;8(4):392-402.
- 272 8. Nduba V, Hoog AHVt, Mitchell E, Onyango P, Laserson K, Borgdorff M. Prevalence of  
273 tuberculosis in adolescents, western Kenya: implications for control programs. In *J Infect*  
274 *Dis*. 2015;35:11-7.
- 275 9. Geldenhuys H, Sorsdahl K, Kafaar F, et al. Risky behaviour and psychosocial correlates  
276 in adolescents - is there a link with tuberculosis? *Afri J psychiatry*. 2011;14(5):383-7.
- 277 10. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and  
278 young adults with perinatally acquired HIV infection. *Annual Review of medicine*.  
279 2010;61:169-85.
- 280 11. Mofenson LM, Cotton MF. The challenges of success: adolescents with perinatal HIV  
281 infection. *J Int AIDS Soc*. 2013;16:18650.
- 282 12. Mahomed H, Ehrlich R, Hawkrigde T, et al. Screening for TB in high school adolescents  
283 in a high burden setting in South Africa. *Tuberculosis (Edinburgh, Scotland)*.  
284 2013;93(3):357-62.

- 285 13. Waako J, Verver S, Wajja A, et al. Burden of tuberculosis disease among adolescents in a  
286 rural cohort in Eastern Uganda. *BMC Infect Dis.* 2013;13:349.
- 287 14. Mandalakas AM, Starke JR. Current concepts of childhood tuberculosis. *Semin Pediatr*  
288 *Infect Dis.* 2005;16(2):93-104.
- 289 15. Powers KA, Miller WC. Critical Review: Building on the HIV Cascade: A  
290 Complementary "HIV States and Transitions" Framework for Describing HIV Diagnosis,  
291 Care, and Treatment at the Population Level. *J Acquir Immune Defic Syndr.*  
292 2015;69(3):341-7.
- 293 16. Joint United Nations Programme on HIV/AIDS (2015). The GAP Report. Geneva,  
294 Switzerland.
- 295 17. Ministry of Health of the Federal Democratic Republic of Ethiopia (2012). Guidelines for  
296 clinical and programmatic management of TB, leprosy and TB/HIV in Ethiopia. Addis  
297 Ababa, Ethiopia.
- 298 18. Mahomed H, Ehrlich R, Hawkrigde T, et al. TB incidence in an adolescent cohort in  
299 South Africa. *PLoS One.* 2013;8(3):e59652.
- 300 19. Jerene D, Lindtjorn B. Disease Progression Among Untreated HIV-Infected Patients in  
301 South Ethiopia: Implications for Patient Care. *J Int AIDS Soc.* 2005;7(3):66.
- 302 20. Jerene D, Naess A, Lindtjorn B. Antiretroviral therapy at a district hospital in Ethiopia  
303 prevents death and tuberculosis in a cohort of HIV patients. *AIDS Res Ther.* 2006;3:10.
- 304 21. Kassa A, Teka A, Shewaamare A, Jerene D. Incidence of tuberculosis and early mortality  
305 in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary  
306 hospital in Addis Ababa, Ethiopia. *Trans R Soc Trop Med Hyg.* 2012;106(6):363-70.
- 307 22. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving  
308 HAART: long term incidence and risk factors in a South African cohort. *AIDS.*  
309 2005;19(18):2109-16.
- 310 23. Yirdaw KD, Jerene D, Gashu Z, et al. Beneficial Effect of Isoniazid Preventive Therapy  
311 and Antiretroviral Therapy on the Incidence of Tuberculosis in People Living with HIV  
312 in Ethiopia. *PloS one.* 2014;9(8):e104557.
- 313 24. Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy  
314 for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the  
315 literature. *J Acquir Immune Defic Syndr.* 2015;68 Suppl 3:S297-305.

- 316
- 317 25. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active  
318 tuberculosis after antiretroviral treatment initiation in Abidjan. *Am J Respir Crit Care*  
319 *Med.* 2005;172(1):123-7
- 320 26. Batista J, de Albuquerque Mde F, Maruza M, et al. Incidence and risk factors for  
321 tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife,  
322 Brazil. *PloS One.* 2013;8(5):e63916.
- 323 27. Guerra-Assuncao JA, Houben RM, Crampin AC, et al. Recurrence due to relapse or  
324 reinfection with *Mycobacterium tuberculosis*: a whole-genome sequencing approach in a  
325 large, population-based cohort with a high HIV infection prevalence and active follow-  
326 up. *The Journal of infectious diseases.* 2015;211 (7):1154-63
- 327 28. Crampin AC, Mwaungulu JN, Mwaungulu FD, et al. Recurrent TB: relapse or  
328 reinfection? The effect of HIV in a general population cohort in Malawi. *AIDS (London,*  
329 *England).* 2010;24 (3):417-26
- 330

331 **Tables**

332

333 **Table 1: Baseline characteristics of adolescents enrolled in chronic HIV care at eight selected health**  
334 **facilities, 2005-2013, Ethiopia**

Characteristic	Value
<b>Region, N (%)</b>	
SNNPR	582 (54.3)
Addis Ababa	490 (45.7)
Total	1072 (100%)
<b>Median age in years</b>	13
<b>Sex, N (%) girls</b>	644 (60.1)
<b>WHO stage, N (%)</b>	
I-II	501 (46.7)
III-IV	544 (50.7)
Missing	27 (2.5)
Total	1072 (100)
<b>Median CD4 (IQR)</b>	228 (106-410)

335

336 **Legend**

337 SNNPR=Southern Nations', Nationalities' and Peoples' Region



338  
339 **Table 2. Cox Regression Analyses of Predictors of pre-ART TB incidence in adolescents living with HIV,**  
340 **2005-2013, Ethiopia**

<b>Variable</b>	<b>Incident TB case</b>	<b>Person-years</b>	<b>Incident rate per 100 PYO</b>	<b>Unadjusted HR (95% CI)</b>	<b>Adjusted HR (95% CI)</b>
<b>Region</b>					
Addis Ababa	69	437.51	15.77 (12.27, 19.96)	Ref	Ref
SNNPR	73	432.53	16.88 (13.23, 21.22)	1.09 (0.79, 1.52)	1.14 (0.80, 1.62)
<b>Sex</b>					
Female	85	531.11	16.00 (12.78, 19.79)	Ref	Ref
Male	57	336.31	16.95 (12.84, 21.96)	1.02 (0.73, 1.43)	1.07 (0.75, 1.52)
<b>Cough*</b>					
No	49	712.90	6.87 (5.08, 9.09)	Ref	Ref
Yes	91	119.32	76.27(61.40, 93.64)	9.51 (6.72, 13.45)	1.85 (1.21, 2.84)
<b>WHO stage*</b>					
I-II	30	640.84	4.68 (3.22, 6.59)	Ref	Ref
III-IV	108	217.73	49.6 (40.9, 59.6)	6.78 (4.48, 10.23)	2.71 (1.69, 4.33)
<b>CD 4 count*</b>					
≥350	42	573.36	7.32 (5.35, 9.81)	Ref	Ref
<350	96	270.77	35.45 (28.72, 43.30)	2.81 (1.92, 4.12)	1.85 (1.21, 2.84)
<b>Pre-ART IPT</b>					
No	139	715.97	19.41 (16.38, 22.85)	Ref	Ref
Yes	3	154.06	1.95 (0.49, 5.30)	0.16 (0.05, 0.50)	0.57 (0.17, 1.86)
<b>Previous history of TB</b>					
No	76	870.04	8.73 (6.88, 10.93)	Ref	Ref
Yes	66	84.84	77.78 (60.16, 98.97)	6.23 (4.45, 8.69)	2.22 (1.51-3.26)

341

342 **Legends:**343 **\* numbers do not add up to 142 because of missing data**

344 SNNPR=Southern Nations', Nationalities', and Peoples' Region

345 HR=Hazard ratio; HR= hazard ratio; PY=person-years

346

347

348

349

350  
351  
352  
353**Table 3. Cox Regression Analyses of Factors Associated with TB incidence rate after ART, 2005-2013, Ethiopia**

<b>Variable</b>	<b>Incident TB case</b>	<b>Person-years</b>	<b>Incident rate per 100 PYO</b>	<b>Unadjusted Hazard Ratio (95% CI)</b>	<b>Adjusted Hazard Ratio (95%CI)</b>
<b>Region</b>					
Addis Ababa	40	2009.76	1.99 (1.44, 2.68)	Ref	Ref
SNNPR	24	833.77	2.88 (1.89, 4.22)	1.96 (1.16, 3.32)	2.69 (1.52, 4.78)
<b>Sex</b>					
Female	25	1638.70	1.53 (1.01, 2.22)	Ref	Ref
Male	39	1202.75	3.24 (2.24, 4.39)	1.01 (0.61, 1.67)	1.09 (0.65, 1.84)
<b>Cough</b>					
Yes	12	557.39	2.15 (1.17, 3.66)	Ref	Ref
No	52	2070.83	2.51 (1.89, 3.27)	1.09 (0.58, 2.05)	1.11 (0.55, 2.21)
<b>WHO stage*</b>					
I-II	12	785.00	1.53 (0.83, 2.59)	Ref	Ref
III-IV	51	2039.84	2.50 (1.88, 3.26)	1.21 (0.64, 2.31)	1.23 (0.63, 2.38)
<b>CD 4 count</b>					
>=200	16	1034.02	0.9(0.51, 1.46)	Ref	Ref
<200	48	1776.82	4.64 (3.42, 6.15)	1.73 (0.98, 3.05)	1.92 (1.07, 3.44)
<b>Ever used IPT</b>					
No	63	2387.82	2.64 (2.04, 3.35)	Ref	Ref
Yes	1	455.71	0.22 (0.01, 1.08)	0.08 (0.01, 0.57)	0.06 (0.01, 0.45)
<b>Previous history of TB</b>					
No	53	2202.88	2.41 (1.80, 3.15)	Ref	Ref
Yes	11	635.26	1.73 (0.86, 3.09)	0.57 (0.29, 1.10)	0.64 (0.32, 1.28)

354 \*Numbers do not add up to 64 because of missing data